Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma

AIDS

Volumn 24, Issue 6, 2010, Pages 851-856

  Montoto, Silvia ^a   Wilson, Jamie ^b   Shaw, Kate ^c   Heath, Maureen ^a   Wilson, Andy ^a   McNamara, Christopher ^b   Orkin, Chloe ^a   Nelson, Mark ^c   Johnson, Margaret ^b   Bower, Mark ^c   Cwynarski, And Kate ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Burkitt's lymphoma; CD4 cell counts; CODOX M IVAC; HIV; Immunological recovery; Intensive chemotherapy

Indexed keywords

ACICLOVIR; AZITHROMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; IFOSFAMIDE; LACTATE DEHYDROGENASE; METHOTREXATE; PENTAMIDINE; PROTEINASE INHIBITOR; RITUXIMAB; RNA DIRECTED DNA POLYMERASE INHIBITOR; VINCRISTINE;

ABDOMINAL BLEEDING; ADULT; AGED; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; ENTEROCOLITIS; EVENT FREE SURVIVAL; GASTROINTESTINAL HEMORRHAGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NEPHROTOXICITY; OVERALL SURVIVAL; PATIENT ASSESSMENT; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BURKITT LYMPHOMA; CD4 LYMPHOCYTE COUNT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; METHOTREXATE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE;

EID: 77949558715     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283301578     Document Type: Article

References (19)

1. Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lym-phoma: AIDS-Malignancies Consortium Trial 010. Blood 2005; 106:1538-1543.
2. Wang ES, Straus DJ, Teruya-Feldstein J, Qin J, Portlock C, Moskowitz C, et al. Intensive chemotherapy with cyclopho-sphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003; 98:1196-1205.
3. Galicier L, Fieschi C, Borie R, Meignin V, Daniel MT, Gerard L, Oksenhendler E. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood 2007; 110:2846-2854.
4. Oriol A, Ribera JM, Bergua J, Gimenez Mesa E, Grande C, Esteve J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer 2008; 113:117-125.
5. Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubi-cin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94:1492-1499.
6. Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S, Nelson M, et al. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med 2008; 9:336-388.
7. Diebold J, Jaffe ES, Raphael M, Warnke RA. Burkitt lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours. Lyon: IARC press; 2001. pp. 181-184.
8. Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lym-phoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008; 112:2248-2260.
9. Cheson BD, Horning SJ, CoiffierB, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
10. Zanussi S, Simonelli C, D'Andrea M, Comar M, Bidoli E, Giacca M, et al. The effects of antineoplastic chemotherapy on HIV disease. AIDS Res Hum Retroviruses 1996; 12:1703-1707.
11. Rizzieri DA, Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer 2004; 100:1438-1448.
12. Bower M, Stebbing J, Tuthill M, Campbell V, Krell J, Holmes P, et al. Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma. Blood 2008; 111:3986-3990.
13. Re A, Cattaneo C, Michieli M, Casari S, Spina M, Rupolo M, et al. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol 2003; 21:4423-4427.
14. Gabarre J, Marcelin AG, Azar N, Choquet S, Levy V, Levy Y, et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica 2004; 89:1100-1108.
15. Serrano D, Carrion R, Balsalobre P, Miralles P, Berenguer J, Buno I, et al. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol 2005; 33:487-494.
16. Sparano JA, Wiernik PH, Hu X, Sarta H, Henry DH, Ratech H. Saquinavir enhances the mucosal toxicity of infusional cyclo-phosphamide, doxorubicin and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. Med Oncol 1998; 15:50-57.
17. Bower M, McCall-Peat N, Ryan N, Davies L, Young AM, Gupta S, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004; 104:2943-2946.
18. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lym-phoma. N Engl J Med 2002; 346:235-242.
19. Dunleavy K, Little RF, Pittaluga S, Grant N, Shovlin M, Steinberg SM, et al. A prospective study of dose-adjusted (DA) EPOCH with rituximab in adults with newly diagnosed Burkitt lym-phoma: a regimen with high efficacy and low toxicity. In: 10th International Conference on Malignant Lymphoma. Lugano, Switzerland; 2008.